BOSTON SCIENTIFIC CORP
For the period ended Mar 31, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 1, 2026
BSX$44.70+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations (Unaudited)
| Three Months EndedMarch 31, | ||
|---|---|---|
| (in millions, except per share data) | 2026 | 2025 |
| Net sales | $5,203 | $4,663 |
| Cost of products sold (excluding amortization expense) | 1,590 | 1,453 |
| Gross profit | 3,614 | 3,210 |
| Operating expenses: | ||
| Selling, general and administrative expenses | 1,781 | 1,597 |
| Research and development expenses | 516 | 443 |
| Royalty expense | 12 | 14 |
| Amortization expense | 232 | 219 |
| Contingent consideration net expense (benefit) | (30) | 5 |
| Restructuring net charges (credits) | 3 | 10 |
| 2,513 | 2,288 | |
| Operating income (loss) | 1,101 | 921 |
| Other income (expense): | ||
| Interest expense | (90) | (82) |
| Other, net | 151 | (34) |
| Income (loss) before income taxes | 1,162 | 805 |
| Income tax expense (benefit) | (176) | 133 |
| Net income (loss) | 1,339 | 672 |
| Net income (loss) attributable to noncontrolling interests | (2) | (2) |
| Net income (loss) attributable to Boston Scientific common stockholders | $1,341 | $674 |
| Net income (loss) per common share — basic | $0.90 | $0.46 |
| Net income (loss) per common share — diluted | $0.90 | $0.45 |
| Weighted-average shares outstanding | ||
| Basic | 1,484.9 | 1,477.2 |
| Diluted | 1,495.0 | 1,493.1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.